Current report
Open the filing on sec.gov
Lakewood-Amedex Biotherapeutics Inc. (LABT)
Nasdaq: LABT · Pharmaceutical Preparations · filing with the SEC since 2025
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202643
Newest filingNov 10 · 8-K
Annual reportn/a
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Draft registration, confidential
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.